229 related articles for article (PubMed ID: 29297899)
21. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
McKean MA; Amaria RN
Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
[TBL] [Abstract][Full Text] [Related]
22. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
Barroso-Sousa R; Tolaney SM
Expert Rev Anticancer Ther; 2020 Nov; 20(11):923-930. PubMed ID: 32930616
[TBL] [Abstract][Full Text] [Related]
24. Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma.
Comito F; Ambrosini V; Sperandi F; Melotti B; Ardizzoni A
Anticancer Drugs; 2018 Nov; 29(10):1026-1029. PubMed ID: 30095443
[TBL] [Abstract][Full Text] [Related]
25. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C
Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab for the treatment of bladder cancer.
Sundahl N; Rottey S; De Maeseneer D; Ost P
Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
[TBL] [Abstract][Full Text] [Related]
27. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
28. The safety of anti PD-1 therapeutics for the treatment of melanoma.
Ramelyte E; Schindler SA; Dummer R
Expert Opin Drug Saf; 2017 Jan; 16(1):41-53. PubMed ID: 27737598
[TBL] [Abstract][Full Text] [Related]
29. Selecting immuno-oncology-based drug combinations - what should we be considering?
Festino L; Vanella V; Trojaniello C; Ascierto PA
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):971-985. PubMed ID: 30169990
[TBL] [Abstract][Full Text] [Related]
30. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
Kähler KC; Kosova K; Bohne AS; Schreiber S; Hauschild A
Eur J Cancer; 2020 Oct; 138():169-171. PubMed ID: 32890812
[No Abstract] [Full Text] [Related]
31. CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy.
Szostak B; Machaj F; Rosik J; Pawlik A
Expert Opin Investig Drugs; 2019 Feb; 28(2):149-159. PubMed ID: 30577709
[TBL] [Abstract][Full Text] [Related]
32. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
33. [Not Available].
Pagès C; Baroudjian B; Lebbé C
Bull Cancer; 2016 Nov; 103 Suppl 1():S132-S137. PubMed ID: 28057176
[TBL] [Abstract][Full Text] [Related]
34. Current and Future Therapies for Advanced Gastric Cancer.
Davidson M; Okines AF; Starling N
Clin Colorectal Cancer; 2015 Dec; 14(4):239-50. PubMed ID: 26524924
[TBL] [Abstract][Full Text] [Related]
35. Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report.
Abdou Y; Kapoor A; Hamad L; Ernstoff MS
Medicine (Baltimore); 2019 Nov; 98(44):e17769. PubMed ID: 31689840
[TBL] [Abstract][Full Text] [Related]
36. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report.
Uemura M; Trinh VA; Haymaker C; Jackson N; Kim DW; Allison JP; Sharma P; Vence L; Bernatchez C; Hwu P; Diab A
J Hematol Oncol; 2016 Sep; 9(1):81. PubMed ID: 27595932
[TBL] [Abstract][Full Text] [Related]
37. [Combinations of chemotherapy or radiotherapy with checkpoint inhibitors].
Ghiringhelli F
Biol Aujourdhui; 2018; 212(3-4):77-79. PubMed ID: 30973135
[TBL] [Abstract][Full Text] [Related]
38. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives.
Atkins MB; Larkin J
J Natl Cancer Inst; 2016 Jun; 108(6):djv414. PubMed ID: 26839346
[TBL] [Abstract][Full Text] [Related]
40. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]